A study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres on duration of response (DoR) and objective response rate (ORR) in hepatocellular carcinoma (HCC) patients (DOORwaY90 Study)
Recruiting
18-99 years
All
Phase
1
10 participants needed
1 Location
Brief description of study
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC (Barcelona clinic liver cancer (BCLC) stage A, BCLC stage B1 and BCLC stage B2).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Hepatocellular carcinoma,Liver Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female , Age 18 or older, Hepatocellular carcinoma
Updated on
01 Aug 2024.
Study ID: 849177
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
